ACY-775
Code | Size | Price |
---|
AG-CR1-3903-M001 | 1 mg | £130.00 |
Quantity:
AG-CR1-3903-M005 | 5 mg | £470.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
+4°C (short term), -20°C (long term).
Images
Documents
Further Information
Alternate Names/Synonyms:
2-((1-(3-Fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide
Appearance:
Off white solid.
CAS:
1375466-18-4
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C17H19FN4O2/c18-14-6-4-5-13(9-14)17(7-2-1-3-8-17)21-16-19-10-12(11-20-16)15(23)22-24/h4-6,9-11,24H,1-3,7-8H2,(H,22,23)(H,19,20,21)
InChiKey:
IYBURCQQEUNLDL-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1375466-18-4. Formula: C17H19FN4O2. MW: 330.4. Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =7.5nM). Displays high selectivity over HDAC1-9 (IC50=1-10µM). Shows improved brain bioavailability compared to tubastatin A (Prod. No. AG-CR1-3900). Induces hyperacetylation of alpha-tubulin in brain without concurrently altering the acetylation of histones. Shows antidepressant activity. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
MDL:
MFCD30533691
Molecular Formula:
C17H19FN4O2
Molecular Weight:
330.4
Package Type:
Vial
Product Description:
Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =7.5nM). Displays high selectivity over HDAC1-9 (IC50=1-10µM). Shows improved brain bioavailability compared to tubastatin A (Prod. No. AG-CR1-3900). Induces hyperacetylation of alpha-tubulin in brain without concurrently altering the acetylation of histones. Shows antidepressant activity. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Purity:
>95% (HPLC)
SMILES:
ONC(=O)C1=CN=C(NC2(CCCCC2)C2=CC(F)=CC=C2)N=C1
Solubility Chemicals:
Soluble in DMSO, methanol or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC: S. Mithraprabhu, et al.; Br. J. Haematol. 162, 559 (2013) | Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer: J.S. Riley, et al.; Cell Death Dis. 4, e951 (2013) | RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth: K.A. Wilson-Edell, et al.; Oncotarget 5, 5165 (2014) | Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability: J. Jochems, et al.; Neuropsychopharmacol. 39, 389 (2014)
Related Products
Product Name | Product Code | Supplier | Nexturastat A | AG-CR1-3901 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nexturastat B | AG-CR1-3902 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DMAPB | AG-CR1-3904 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PMPH | AG-CR1-3905 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DABPH | AG-CR1-3906 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MBIMPH | AG-CR1-3907 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MBIMPH F-Analog 1 . HCl | AG-CR1-3908 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MBIMPH F-Analog 2 | AG-CR1-3909 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||